Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Botox | OnabotulinumtoxinA | Neurogenic detrusor overactivity | List with clinical criteria and/or conditions | Complete | ||
| Botox | OnabotulinumtoxinA | Migraine | Do not list | Complete | ||
| Botox | OnabotulinumtoxinA | Urinary incontinence | List with criteria/condition | Complete | ||
| Bosulif (RFA) | Bosutinib | Chronic Myeloid Leukemia | N/A | Complete | ||
| Bosulif | Bosutinib | Chronic Myeloid Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Blincyto (Resubmission) | Blinatumomab | Acute Lymphoblastic Leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Blincyto | Blinatumomab | Withdrawn | ||||
| Blincyto | Blinatumomab | Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Blincyto | Blinatumomab | Acute Lymphoblastic Leukemia (pediatric) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Blincyto | Blinatumomab | Acute Lymphoblastic Leukemia | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 29, 2024